


RCE/1600



REQUEST

FOR

CONTINUED EXAMINATION (RCE)

FEB 24 2003

TRANSMITTAL

ADDRESS TO:

Box RCE

Commissioner of Patents
Washington, D.C. 20231

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-captioned application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application.

Application Number	1346,069
Filing Date	July 1, 1999
First Named Inventor	KEYT
Group Art Unit	1646
Examiner Name	C. Kaufman
Attorney Docket No.	A-62326-2/RFT/THR 468648-978

I hereby certify that this document is being deposited with the U.S. Postal Service with sufficient postage as first class mail addressed to Commissioner for Patents, Box RCE, Washington, D.C. 20231 on this 18th day of February, 2003.

Name: *Monica Carlos* MONICA E. CARLOS

RECEIVED
TECH CENTER 1600/2000
FEB 7 2003

1. Submission required under 37 C.F.R. § 1.114

- a. Previously submitted
 - i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____ (Any unentered amendment(s) referred to above will be entered.)
 - ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - iii. Other: 02/26/2003 CV0111 00000145 09346069
- b. Enclosed
 - i. Amendment and Response to Final Office Action 03 FC:1801 750.00 OP
 - ii. Assignee's Consent to Inventorship Correction Under 37 C.F.R. § 1.48(A) 04 FC:1202 36.00 OP
 - iii. Supplemental Declaration for Patent Application 05 FC:1203 280.00 OP
 - iv. Other: Request for Extension of Time of Three Months and Check in the amount of \$930
 - v. Request to Correct Inventorship and Check in the amount of \$130

2. Miscellaneous

- a. Suspension of action on the above-captioned application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed three months; Fee under 37 C.F.R. § 1.17(i) required.)
- b. Other:

3. Fees

The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. The Fees are calculated as follows:

	AMOUNT	<input checked="" type="checkbox"/>	Large Entity	<input type="checkbox"/>	Small Entity
i. <input checked="" type="checkbox"/> RCE BASIC FEE	\$ 750		\$ 750.00		\$ 375.00
ii. <input checked="" type="checkbox"/> EXTENSION FEES	\$ 930		Three-Month	\$ 930.00	\$ 465.00
iii. <input checked="" type="checkbox"/> OTHER (MULTIPLE DEPENDENT CLAIMS (\$280) AND 2 EXTRA CLAIMS IN EXCESS OF 20 (\$36.00))	\$ 316				\$
- b. Checks in the amount of \$ 1066 (filing fee), \$930 (ext.) and \$130 (Request) are enclosed. The Commissioner is hereby authorized to charge any variance between the amount enclosed and the Patent Office charges to Deposit Account No. 50-2319 (Our Order No. A-62326-2 468648-978).
- c. The Commissioner is hereby authorized to charge the fees as indicated above, charge any variance or credit any overpayments, to Deposit Account No. 50-2319 (Our Order No. A-62326-2 468648-978).

SUBMITTED BY

Typed or Printed Name	Richard F. Trecartin	Complete (if applicable)
Signature	<i>Richard F. Trecartin</i>	Registration No. 31,801 Date 2/18/03



PATENT & TRADEMARK OFFICE
Attorney Docket No: A-62326-2/RFT/THR 68648-998
(Genentech Ref.: P0965P1)

FEB 27 2003

#20/D
DRAFT
3-7-03
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Bruce A. Keyt, et al.	Examiner:	C. Kaufman
Serial No.:	09/346,069		
Filing Date:	July 1, 1999		
Title:	NUCLEIC ACIDS ENCODING VARIANTS OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR		
	Group Art Unit: 1646		

AMENDMENT AND RESPONSE
TO FINAL OFFICE ACTION

Box RCE
Assistant Commissioner for Patents
Washington, D.C. 20231



32940

PATENT TRADEMARK OFFICE

I hereby certify that this document, including listed enclosures, is being sent via First Class U.S. mail addressed to: Box RCE, Assistant Commissioner for Patents, Washington, D.C. 20231 on this 18th day of February, 2003.

Signature: Monica Carlos
MONICA E. CARLOS

Sir:

This Amendment is submitted with a Request for Continued Examination under 37 C.F.R. § 1.114 and is accompanied by the required fee as set forth in 37 C.F.R. § 1.17(e). A final Office Action was mailed March 14, 2002 and a Notice of Appeal was filed September 16, 2002. Therefore, enclosed herein is a fee for a three month extension to maintain the pendency of the subject application up to and including Tuesday, February 18, 2003.

The Commissioner is authorized to charge any fees, including extension fees or other relief, which may be required, or credit any overpayment to Deposit Account No. 502319.

Please amend the referenced application as follows:

IN THE CLAIMS:

18. A composition of matter comprising:

D1
a) a purified polypeptide, said polypeptide comprising a non-naturally occurring vascular endothelial cell growth factor (VEGF) variant of native VEGF wherein said variant